Bioactivity of PEGylated Graphene Oxide Nanoparticles Combined with Near-Infrared Laser Irradiation Studied in Colorectal Carcinoma Cells

Central focus in modern anticancer nanosystems is given to certain types of nanomaterials such as graphene oxide (GO). Its functionalization with polyethylene glycol (PEG) demonstrates high delivery efficiency and controllable release of proteins, bioimaging agents, chemotherapeutics and anticancer drugs. GO–PEG has a good biological safety profile, exhibits high NIR absorbance and capacity in photothermal treatment. To investigate the bioactivity of PEGylated GO NPs in combination with NIR irradiation on colorectal cancer cells we conducted experiments that aim to reveal the molecular mechanisms of action of this nanocarrier, combined with near-infrared light (NIR) on the high invasive Colon26 and the low invasive HT29 colon cancer cell lines. During reaching cancer cells the phototoxicity of GO–PEG is modulated by NIR laser irradiation. We observed that PEGylation of GO nanoparticles has well-pronounced biocompatibility toward colorectal carcinoma cells, besides their different malignant potential and treatment times. This biocompatibility is potentiated when GO–PEG treatment is combined with NIR irradiation, especially for cells cultured and treated for 24 h. The tested bioactivity of GO–PEG in combination with NIR irradiation induced little to no damages in DNA and did not influence the mitochondrial activity. Our findings demonstrate the potential of GO–PEG-based photoactivity as a nanosystem for colorectal cancer treatment.

Download Full-text

Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells

Biomolecules ◽

10.3390/biom9120820 ◽

2019 ◽

Vol 9 (12) ◽

pp. 820 ◽

Cited By ~ 2

Author(s):

Dmitry Polikarpov ◽

Liuen Liang ◽

Andrew Care ◽

Anwar Sunna ◽

Douglas Campbell ◽

...

Keyword(s):

Bladder Cancer ◽

Urothelial Carcinoma ◽

Cancer Cells ◽

Near Infrared ◽

Carcinoma Cells ◽

Infrared Light ◽

Upconversion Nanoparticles ◽

Silica Layer ◽

Bladder Cancer Cells

Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.

Download Full-text

Sulfobetaine methacrylate-albumin-coated graphene oxide incorporating IR780 for enhanced breast cancer phototherapy

Nanomedicine ◽

10.2217/nnm-2020-0460 ◽

2021 ◽

Vol 16 (6) ◽

pp. 453-464

Author(s):

Bruna L Melo ◽

Rita Lima-Sousa ◽

Cátia G Alves ◽

Paula Ferreira ◽

André F Moreira ◽

...

Keyword(s):

Breast Cancer ◽

Graphene Oxide ◽

Bovine Serum Albumin ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Colloidal Stability ◽

Near Infrared ◽

Infrared Light ◽

Near Infrared Light ◽

Biologically Relevant

Aim: Enhance the colloidal stability and photothermal capacity of graphene oxide (GO) by functionalizing it with sulfobetaine methacrylate (SBMA)-grafted bovine serum albumin (BSA; i.e., SBMA- g-BSA) and by loading IR780, respectively. Materials & methods: SBMA- g-BSA coating and IR780 loading into GO was achieved through a simple sonication process. Results: SBMA- g-BSA-functionalized GO (SBMA-BSA/GO) presented an adequate size distribution and cytocompatibility. When in contact with biologically relevant media, the size of the SBMA-BSA/GO only increased by 8%. By loading IR780 into SBMA-BSA/GO, its photothermal capacity increased by twofold. The combination of near infrared light with SBMA-BSA/GO did not induce photocytotoxicity on breast cancer cells. In contrast, the interaction of IR780-loaded SBMA-BSA/GO with near infrared light caused the ablation of cancer cells. Conclusion: IR780-loaded SBMA-BSA/GO displayed an improved colloidal stability and phototherapeutic capacity.

Download Full-text

The Characters of Graphene Oxide Nanoparticles and Doxorubicin Against HCT-116 Colorectal Cancer Cells In Vitro

Journal of Gastrointestinal Cancer ◽

10.1007/s12029-021-00625-x ◽

2021 ◽

Author(s):

Shaima Rabeea Banoon ◽

Abdolmajid Ghasemian

Keyword(s):

Colorectal Cancer ◽

Graphene Oxide ◽

Cancer Cells ◽

Oxide Nanoparticles ◽

Colorectal Cancer Cells ◽

Hct 116

Download Full-text

[Mn(PaPy2Q)(NO)]ClO4, a Near-Infrared Light activated release of Nitric Oxide drug as a nitric oxide donor for therapy of human prostate cancer cells in vitro and in vivo

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2021.111388 ◽

2021 ◽

Vol 137 ◽

pp. 111388

Author(s):

Yuwan Zhao ◽

Zhuo Li ◽

Huancheng Tang ◽

Shanhong Lin ◽

Wenfeng Zeng ◽

...

Keyword(s):

Prostate Cancer ◽

Nitric Oxide ◽

Cancer Cells ◽

Near Infrared ◽

Nitric Oxide Donor ◽

Infrared Light ◽

Human Prostate Cancer ◽

Prostate Cancer Cells

Download Full-text

Near-Infrared Light-Activated Pt@Au Nanorings-Based Probe for Fluorescence Imaging and Targeted Photothermal Therapy of Cancer Cells

ACS Applied Bio Materials ◽

10.1021/acsabm.9b00712 ◽

2019 ◽

Vol 2 (11) ◽

pp. 5012-5020

Author(s):

Hui Zhang ◽

Yiming Wang ◽

Hua Zhong ◽

Jie Li ◽

Caifeng Ding

Keyword(s):

Cancer Cells ◽

Fluorescence Imaging ◽

Photothermal Therapy ◽

Near Infrared ◽

Infrared Light ◽

Near Infrared Light

Download Full-text

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant

Cell Death and Disease ◽

10.1038/s41419-020-03232-z ◽

2020 ◽

Vol 11 (11) ◽

Author(s):

Michael Fichtner ◽

Emir Bozkurt ◽

Manuela Salvucci ◽

Christopher McCann ◽

Katherine A. McAllister ◽

...

Keyword(s):

Colorectal Cancer ◽

Colon Cancer ◽

Cancer Cells ◽

Cell Lines ◽

Molecular Mechanisms ◽

Mononuclear Cells ◽

Caspase 8 ◽

Colon Cancer Cells ◽

Apoptosis Pathway ◽

Iap Antagonist

AbstractColorectal cancer is a molecularly heterogeneous disease. Responses to genotoxic chemotherapy in the adjuvant or palliative setting vary greatly between patients, and colorectal cancer cells often resist chemotherapy by evading apoptosis. Antagonists of an inhibitor of apoptosis proteins (IAPs) can restore defective apoptosis signaling by degrading cIAP1 and cIAP2 proteins and by inhibition of XIAP. Due to the multiple molecular mechanisms-of-action of these targets, responses to IAP antagonist may differ between molecularly distinct colon cancer cells. In this study, responses to the IAP antagonist Birinapant and oxaliplatin/5-fluorouracil (5-FU) were investigated in 14 colon cancer cell lines, representing the consensus molecular subtypes (CMS). Treatment with Birinapant alone did not result in a substantial increase in apoptotic cells in this cell line panel. Annexin-V/PI assays quantified by flow cytometry and high-content screening showed that Birinapant increased responses of CMS1 and partially CMS3 cell lines to oxaliplatin/5-FU, whereas CMS2 cells were not effectively sensitized. FRET-based imaging of caspase-8 and -3 activation validated these differences at the single-cell level, with CMS1 cells displaying sustained activation of caspase-8-like activity during Birinapant and oxaliplatin/5-FU co-treatment, ultimately activating the intrinsic mitochondrial apoptosis pathway. In CMS2 cell lines, Birinapant exhibited synergistic effects in combination with TNFα, suggesting that Birinapant can restore extrinsic apoptosis signaling in the context of inflammatory signals in this subtype. To explore this further, we co-cultured CMS2 and CMS1 colon cancer cells with peripheral blood mononuclear cells. We observed increased cell death during Birinapant single treatment in these co-cultures, which was abrogated by anti-TNFα-neutralizing antibodies. Collectively, our study demonstrates that IAP inhibition is a promising modulator of response to oxaliplatin/5-FU in colorectal cancers of the CMS1 subtype, and may show promise as in the CMS2 subtype, suggesting that molecular subtyping may aid as a patient stratification tool for IAP antagonists in this disease.

Download Full-text